1. Search Result
Search Result
Isoforms Recommended: EGFR/ErbB1/HER1
Results for "

HER1

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

3

Inhibitory Antibodies

28

Recombinant Proteins

3

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15196
    TAK-285
    2 Publications Verification

    EGFR Cancer
    TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity [1]. TAK-285 can cross the blood-brain barrier (BBB) .
    TAK-285
  • HY-10530
    Varlitinib
    1 Publications Verification

    ASLAN001; ARRY-334543

    EGFR Cancer
    Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively [1].
    Varlitinib
  • HY-10260
    Vandetanib
    Maximum Cited Publications
    21 Publications Verification

    ZD6474

    VEGFR Autophagy Apoptosis Cancer
    Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) [1].
    Vandetanib
  • HY-12010
    BMS-599626 Hydrochloride
    3 Publications Verification

    AC480 Hydrochloride

    EGFR Cancer
    BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy [1] .
    BMS-599626 Hydrochloride
  • HY-110333

    EGFR Cancer
    BMS-599626 dihydrochloride is a small molecule pan-HER (human epidermal growth factor receptor) kinase inhibitor. BMS-599626 dihydrochloride primarily targets HER1 (IC50=20 nmol/L) and HER2 (IC50=30 nmol/L) kinase activity in the HER family. BMS-599626 inhibits the kinase activity of HER1 and HER2 by competing with their ATP-binding sites, and can inhibit the downstream signaling pathway by blocking the heterodimer formation of HER1 and HER2. BMS-599626 dihydrochloride can be used to study the antitumor effects of multiple HER1 or HER2 overexpressed tumor models [1].
    BMS-599626 dihydrochloride
  • HY-10530A

    ASLAN001 tosylate; ARRY-334543 tosylate

    EGFR Cancer
    Varlitinib (ASLAN001) tosylate is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively [1].
    Varlitinib tosylate
  • HY-10260B

    ZD6474 hydrochloride

    VEGFR Autophagy Apoptosis Cancer
    Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) [1].
    Vandetanib hydrochloride
  • HY-10260A

    ZD6474 trifluoroacetate

    VEGFR Autophagy Apoptosis Cancer
    Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) [1].
    Vandetanib trifluoroacetate
  • HY-10260R

    VEGFR Autophagy Apoptosis Cancer
    Vandetanib (Standard) is the analytical standard of Vandetanib. This product is intended for research and analytical applications. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) [1].
    Vandetanib (Standard)
  • HY-10260S1

    Isotope-Labeled Compounds VEGFR Autophagy Apoptosis Cancer
    Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].
    Vandetanib-d4
  • HY-10260S

    ZD6474-d6

    Isotope-Labeled Compounds VEGFR Autophagy Apoptosis Cancer
    Vandetanib-d6 is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].
    Vandetanib-d6
  • HY-10251

    AC480

    EGFR Cancer
    BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy [1] .
    BMS-599626
  • HY-101042

    Tyrphostin AG 494

    EGFR CDK Cancer
    AG-494 (Tyrphostin AG 494) is a potent and selective EGFR tyrosine kinase inhibitor (IC50=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC50s 1.1, 39, 45 and 6 μM, respectively. AG-494 blocks Cdk2 activation and inhibits EGF-dependent DNA synthesis [1] .
    AG-494
  • HY-10260S2

    ZD6474-13C6

    Isotope-Labeled Compounds VEGFR Autophagy Apoptosis Cancer
    Vandetanib-13C6 is a deuterated labeled Vandetanib [1]. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
    Vandetanib-13C6
  • HY-P99628

    EGFR Cancer
    Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity [1].
    Futuximab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: